COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03648814
Recruitment Status : Recruiting
First Posted : August 27, 2018
Last Update Posted : April 1, 2020
Information provided by (Responsible Party):
Weerawat Kiddee, Prince of Songkla University

Brief Summary:
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Condition or disease Intervention/treatment Phase
Glaucoma, Neovascular Vascular Endothelial Growth Factor Overexpression Procedure: Intracameral injection Procedure: Intravitreal injection Not Applicable

Detailed Description:
The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : July 1, 2022
Estimated Study Completion Date : July 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Intracameral injection
Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
Procedure: Intracameral injection
A/C injection of 1.25 mg/0.05 mL bevacizumab

Experimental: Intravitreal injection
Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
Procedure: Intravitreal injection
Vitreous injection of 1.25 mg/0.05 mL bevacizumab

Primary Outcome Measures :
  1. regression of nevolascularization [ Time Frame: 2 months ]
    Amount of nevolascular of iris and angle regression

Secondary Outcome Measures :
  1. IOP reduction [ Time Frame: 2 months ]
    IOP reduction at 2-month visit compare to baseline

  2. Injection complication [ Time Frame: 2 days ]
    Hyphema, IOP spike

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of neovascular glaucoma
  2. The patients having IOP > 21 mmHg, having the indication for trabeculectomy
  3. The patients' age of at least 18-year-old
  4. The patients having visual potential at least hand motion.
  5. Present of NVI or NVA.
  6. Willing and able to provide informed consent to participate in the study
  7. Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits

Exclusion Criteria:

  1. One eye patient
  2. Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
  3. Cannot obtain endothelial cell count.
  4. History of bevacizumab or fluorescence dye allergy.
  5. Active infectious ocular disease including endophthalmitis and corneal ulcer
  6. History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension
  7. Has or planning to be pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03648814

Layout table for location contacts
Contact: Assoc.Prof.Weerawat Kiddee, MD +66874954626

Layout table for location information
Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University Recruiting
Hat-yai, Songkhla, Thailand, 90110
Contact: WEERAWAT KIDDEE, MD    66-81271-0644   
Sponsors and Collaborators
Prince of Songkla University
Layout table for investigator information
Principal Investigator: Assoc.Prof.Weerawat Kiddee, MD Prince of Songkla University

Layout table for additonal information
Responsible Party: Weerawat Kiddee, Assoc. Prof., Prince of Songkla University Identifier: NCT03648814    
Other Study ID Numbers: REC6100321
First Posted: August 27, 2018    Key Record Dates
Last Update Posted: April 1, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Weerawat Kiddee, Prince of Songkla University:
Neovascular glaucoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Neovascular
Ocular Hypertension
Eye Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors